D-0389-2024 Class III Terminated

Recalled by Novitium Pharma LLC — East Windsor, NJ

FDA drug recall D-0389-2024 was initiated by Novitium Pharma LLC on Mar 4, 2024 and is designated Class III. Reason for recall: Cross Contamination with Other Products:(mycophenolate mofetil). The recall status is terminated (terminated Mar 21, 2025). Affected quantity: 3,940 1000-count bottles.

Recall details

Product Type
Drugs
Report Date
Mar 27, 2024
Initiation Date
Mar 4, 2024
Termination Date
Mar 21, 2025
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
3,940 1000-count bottles

Product description

Digoxin Tablets, USP 125mcg, (0.125 mg), 1000-count bottle, Rx Only, Manufactured by: Novitium Pharma LLC., 70 Lake Drive, East Windsor, New Jersey 08520, NDC 70954-201-20

Reason for recall

Cross Contamination with Other Products:(mycophenolate mofetil).

Distribution pattern

Nationwide in the USA

Code information

Lot #: M23172A, Exp 01/31/2025

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0389-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0389-2024. Report a data issue: hello@regdatalab.com.